Synthetic Genomics Asset Acquisition (Details) - USD ($)								12 Months Ended
	Jan. 31, 2021	Jan. 31, 2020	May 09, 2019	Feb. 28, 2019	Jan. 31, 2019	Dec. 20, 2018	Feb. 28, 2018	Dec. 31, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash paid for productive assets							$ 8,000,000
Cash paid acquisition of assets				$ 7,000,000	$ 1,000,000		1,000,000
Issuance of common stock and conversion of deferred consideration for asset acquisition							$ 27,000,000	$ 1,462,000
Maximum potential milestone payments						$ 39,500,000
Derivative liability, fair value			$ 2,900,000						$ 1,117,000
Gain on derivative liability			$ 2,000,000					1,117,000	1,724,000
Interest expense								$ 931,000	1,013,000
Derivative liability related to asset acquisition									2,800,000
Acquired IPR&D expense									$ 6,767,000
Forecast [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash paid acquisition of assets	$ 2,000,000	$ 1,000,000
Synthetic Genomics Inc [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Conversion of Stock, Shares Converted			516,976